Carl Zeiss Licences Digital Pathology from Olympus

17-07-2012: Carl Zeiss Microscopy GmbH and Olympus America Inc. have signed a nonexclusive worldwide licensing agreement allowing Carl Zeiss to access an extensive portfolio of patents held by Olympus in the field of digital pathology and virtual microscopy. The patents included in the licensing deal cover methods and equipment for creating, storing and delivering virtual microscopy slides. The technology enables individuals to view and share high-resolution virtual microscopy images over the Internet.

"The handling of digital data has become a major driver of the development of modern microscopy,” said Dr. Bernhard Ohnesorge, Member of the Board and General Manager BioSciences Division of Carl Zeiss Microscopy. “Integrating the virtual slide functionality into our research microscope systems will enable our customers to become more efficient and to explore new scientific approaches. This will help them to better understand the root causes of the most challenging diseases.”

“Global adoption of digital slide scanning continues to expand into new medical and scientific applications,” said Brad Burklow, Executive Director Business Development, Scientific Equipment Group, Olympus Corporation of the Americas. “Olympus is the holder of many important patents in this area, and we feel it is vital to allow broad access to these technologies in order to advance the field of pathology and medical research. We are confident that leveraging these technologies will enhance healthcare for patients around the world.”

The companies are not making specific terms and conditions of the agreement public.

Facts, background information, dossiers
More about Carl Zeiss
  • News

    ZEISS ends successful fiscal year 2012/13

    ZEISS has brought fiscal year 2012/13 to a successful conclusion with an all-time high in revenue. The company put in a good performance in some sectors despite a partly difficult economic environment and generated revenue totaling EUR 4.190 billion (prior year: EUR 4.163 billion) and earni ... more

    ZEISS Executive Board enlarged

    The start of calendar year 2014 will see some changes to the Executive Board of Carl Zeiss AG headed by President and CEO Dr. Michael Kaschke. The enlargement of the Executive Board and the reallocation of responsibilities are aimed at driving forward the consistent positioning of ZEISS as ... more

    Carl Zeiss Meditec reaffirms its annual target

    Facing a slight downturn in the overall market, Medical technology provider Carl Zeiss Meditec AG raised its revenue by 2.9 percent to EUR 649 million (previous year: EUR 630.8 million) in the first nine months of financial year 2011/2012. In the first nine months of the current financial y ... more

More about Olympus
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE